Patents by Inventor Christopher R. COGLE

Christopher R. COGLE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230092232
    Abstract: Provided herein are compositions and methods for eliciting a desired immune response in a subject in need thereof. The compositions and methods are particularly useful as anti-cancer immune therapy by exploiting a subject's propensity for drug (e.g small molecule) hypersensitivity. Of particular significance is the application in personalized immune therapy for cancer patients utilizing or repurposing existing FDA approved drugs.
    Type: Application
    Filed: February 26, 2021
    Publication date: March 23, 2023
    Applicant: University of Florida Research Foundation, Incorporated
    Inventors: David A. Ostrov, Christopher R. Cogle
  • Patent number: 11014876
    Abstract: Cancer is a disease for which there remains a great unmet medical need, and therefore the discovery and development of new antineoplastic agents is critically important. The present invention relates in part to new therapeutic compounds with antineoplastic activity. Provided herein are polyamine sulfonamides such as compounds of Formula (I), or pharmaceutically acceptable salts thereof, which may be used in the treatment and/or prevention of diseases such as cancer. Also provided herein are pharmaceutical compositions and kits comprising the inventive compounds. Furthermore, the present invention provides methods of treating and/or preventing diseases (e.g., cancer) using compounds of Formula (I), or pharmaceutically acceptable salts thereof or pharmaceutical compositions thereof. Other methods provided include methods for inducing apoptosis of a cell, as well as methods for inhibiting alpha-enolase enzymatic activity in vivo and in vitro.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: May 25, 2021
    Assignees: University of Florida Research Foundation, Inc., Torrey Pines Institute for Molecular Studies
    Inventors: Christopher R. Cogle, Amy M. Meacham, Peter P. Sayeski, Marcello A. Giulianotti, Richard A. Houghten, Gregory S. Welmaker
  • Patent number: 10322149
    Abstract: A method of treating or preventing graft versus host disease (GVHD) in a subject receiving a graft comprising hematopoietic cells is provided. The method comprises contacting the graft ex vivo with an amount of a Myxoma Virus effective to inhibit proliferation of T lymphocytes in the graft and to treat or prevent GVHD in the host subject following infusion of the graft into the subject. After the contacting of the graft with the Myxoma Virus, the method comprises transplanting the virus-treated graft into the subject.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: June 18, 2019
    Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: Douglas G. McFadden, Eric C. Bartee, Christopher R. Cogle
  • Publication number: 20180297942
    Abstract: Cancer is a disease for which there remains a great unmet medical need, and therefore the discovery and development of new antineoplastic agents is critically important. The present invention relates in part to new therapeutic compounds with antineoplastic activity. Provided herein are polyamine sulfonamides such as compounds of Formula (I), or pharmaceutically acceptable salts thereof, which may be used in the treatment and/or prevention of diseases such as cancer. Also provided herein are pharmaceutical compositions and kits comprising the inventive compounds. Furthermore, the present invention provides methods of treating and/or preventing diseases (e.g., cancer) using compounds of Formula (I), or pharmaceutically acceptable salts thereof or pharmaceutical compositions thereof. Other methods provided include methods for inducing apoptosis of a cell, as well as methods for inhibiting alpha-enolase enzymatic activity in vivo and in vitro.
    Type: Application
    Filed: November 4, 2016
    Publication date: October 18, 2018
    Applicants: University of Florida Research Foundation, Inc., Torrey Pines Institute for Molecular Studies
    Inventors: Christopher R. Cogle, Amy M. Meacham, Peter P. Sayeski, Marcello A. Giulianotti, Richard A. Houghten, Gregory S. Welmaker
  • Publication number: 20180064760
    Abstract: A method of treating or preventing graft versus host disease (GVHD) in a subject receiving a graft comprising hematopoietic cells is provided. The method comprises contacting the graft ex vivo with an amount of a Myxoma Virus effective to inhibit proliferation of T lymphocytes in the graft and to treat or prevent GVHD in the host subject following infusion of the graft into the subject. After the contacting of the graft with the Myxoma Virus, the method comprises transplanting the virus-treated graft into the subject.
    Type: Application
    Filed: August 14, 2017
    Publication date: March 8, 2018
    Inventors: Douglas G. McFadden, Eric C. Bartee, Christopher R. Cogle
  • Patent number: 9730960
    Abstract: A method of treating or preventing graft versus host disease (GVHD) in a subject receiving a graft comprising hematopoietic cells is provided. The method comprises contacting the graft ex vivo with an amount of a Myxoma Virus effective to inhibit proliferation of T lymphocytes in the graft and to treat or prevent GVHD in the host subject following infusion of the graft into the subject. After the contacting of the graft with the Myxoma Virus, the method comprises transplanting the virus-treated graft into the subject.
    Type: Grant
    Filed: June 11, 2012
    Date of Patent: August 15, 2017
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Douglas G. McFadden, Eric C. Bartee, Christopher R. Cogle
  • Publication number: 20140328804
    Abstract: A method of treating or preventing graft versus host disease (GVHD) in a subject receiving a graft comprising hematopoietic cells is provided. The method comprises contacting the graft ex vivo with an amount of a Myxoma Virus effective to inhibit proliferation of T lymphocytes in the graft and to treat or prevent GVHD in the host subject following infusion of the graft into the subject. After the contacting of the graft with the Myxoma Virus, the method comprises transplanting the virus-treated graft into the subject.
    Type: Application
    Filed: June 11, 2012
    Publication date: November 6, 2014
    Applicant: University of Florida Research Foundation, Inc.
    Inventors: Douglas G. McFadden, Eric C. Bartee, Christopher R. Cogle
  • Publication number: 20110280874
    Abstract: Hemangioblasts in adult bone marrow participate in new blood vessel formation. By modulating the differentiation of hemangioblasts into blood vessel cells, angiogenesis in a particular tissue can be increased or decreased. The present invention features compositions and methods for reducing tumor vasculogenesis, treating leukemia, and/or treating or preventing leukemia relapse. In particular, the invention provides an SDF-1 binding agent (e.g., antibody, antisense, ribozyme) for the treatment or prevention of a neoplasia, such as leukemia. Intravitreal injection of antibodies that block SDF-1 activity inhibited induced retinal neovascularization mediated by hemangioblasts. Anti-SDF-1 ribozymes and SDF-1 anti-sense RNA expression constructs significantly reduced migration of cells that create new vessels in the eye.
    Type: Application
    Filed: January 22, 2010
    Publication date: November 17, 2011
    Inventors: Edward W. Scott, Christopher R. Cogle
  • Publication number: 20090291087
    Abstract: Hemangioblasts in adult bone marrow participate in new blood vessel formation. By modulating the differentiation of hemangioblasts into blood vessel cells, angiogenesis in a particular tissue can be increased or decreased. The present invention features compositions and methods for reducing tumor vasculogenesis, treating leukemia, and/or treating or preventing leukemia relapse. In particular, the invention provides an SDF-1 binding agent (e.g., antibody, antisense, ribozyme) for the treatment or prevention of a neoplasia, such as leukemia. Intravitreal injection of antibodies that block SDF-1 activity inhibited induced retinal neovascularization mediated by hemangioblasts. Anti-SDF-1 ribozymes and SDF-1 anti-sense RNA expression constructs significantly reduced migration of cells that create new vessels in the eye.
    Type: Application
    Filed: January 23, 2009
    Publication date: November 26, 2009
    Applicant: University of Florida Research Foundation, Inc.
    Inventors: Edward W. SCOTT, Christopher R. COGLE